Fig. 6

The mechanistic study of anti-tumor effects induced by LNP-M/pR282W-mAb. A and B The levels of CD107a and IFN-γ expression in NK cells within TILs. C and D The expression of CD107a and IFN-γ in NKT cells within TILs. D and E The percentages of CD103⁺CD11c⁺ and CD8⁺CD11c⁺ cells within tumors. G and H The expression of DC activation markers (CD80, CD86, and MHC) on CD11c⁺ cells within tumors. I and J The percentages of multifunctional CD8⁺ T cells expressing IFN-γ, IL-2, and TNF-α in tumors. K-M The impact of blocking CD8⁺ T cells, NK cells, or CD4⁺ T cells on animal survival. Each animal (n = 10 per group) received intraperitoneal injections of 0.5 mg anti-mouse CD4, CD8α or NK1.1 mAb two days before the first dose of LNP-M/pR282W-mAb. The second and third doses were administered on days 5 and 12. N and O Memory immunity in mice treated with LNP-M/pR282W-mAb. Mice treated with LNP-M/pR282W-mAb were rechallenged with MC38-p53^KO/R282W cells on the left flank, with naïve mice serving as the control group. N Tumor growth curves. O Survival rate. P Representative images of FACS and statistical analysis of CD8⁺ T cells labeled by CD44 and CD62L in the splenocytes from both groups. Q Splenic memory T cells from mice treated with LNP-M/pR282W-mAb. Mice carrying subcutaneous MC38-p53^KO/R282W tumors were treated with LNP-M/pR282W-mAb, and the spleen was taken for FACS analyses of CD44^lowCD62L^high (stem cell memory): CD44^highCD62L^high (central memory), and CD44^highCD62L^low (effector memory) CD8.⁺ T cells. Data were presented as means ± SD. Statistical significance was set at **p < 0.01, ***p < 0.001, and ****p < 0.0001